Lenalidomide in follicular lymphoma
Cette étude passe en revue les essais évaluant l’efficacité du lénalidomide, seul ou en combinaison avec le rituximab, chez des patients atteints d’un lymphome folliculaire
Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as first-line therapy and as treatment for patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single agent rituximab and may become an alternative to chemoimmunotherapy.
Blood 2020